Microscopic Colitis: The Hidden Cause of Chronic Watery Diarrhea

What Is Microscopic Colitis?

Microscopic colitis is a chronic inflammatory bowel disease of the colon defined by a single, counterintuitive paradox: the colonoscopy looks completely normal. The mucosa appears pristine. There are no ulcers, no polyps, no visible inflammation. And yet the patient has been running to the bathroom five to ten times a day — often waking in the middle of the night — for months or years.

The diagnosis cannot be made by colonoscopy alone. It requires biopsy. Under the microscope, the pathologist finds one of two distinct patterns that define the two subtypes of the disease.

Lymphocytic Colitis (LC)

In lymphocytic colitis, the hallmark finding is an excess of intraepithelial lymphocytes — immune cells that have migrated into the lining of the colon. The diagnostic threshold is more than 20 intraepithelial lymphocytes per 100 colonocytes. The subepithelial collagen band is normal or only mildly thickened. Think of it as an immune infiltrate without the structural scaffolding change.

Collagenous Colitis (CC)

In collagenous colitis, the defining feature is a thickened subepithelial collagen band — the protein scaffold just beneath the epithelial surface. Normal collagen band thickness is less than 5 micrometers. In collagenous colitis, it exceeds 10 micrometers. This thickened band, combined with lymphocytic infiltration, impairs the colon's ability to absorb water, producing the signature secretory diarrhea. Collagenous colitis is more strongly associated with PPIs than lymphocytic colitis.

Epidemiology: Far More Common Than Most Physicians Realize

Microscopic colitis is dramatically underdiagnosed. The incidence — 10 to 15 cases per 100,000 people per year — is approximately equal to that of Crohn's disease. Yet Crohn's disease has robust public awareness and dedicated IBD clinics. Microscopic colitis is frequently never considered, particularly in patients who receive a colonoscopy that returns "normal" and are subsequently told they have IBS.

Several epidemiological patterns define the population at highest risk:

• Sex: Women are 5 to 10 times more affected than men — one of the largest sex disparities in gastroenterology.
• Age: Peak incidence occurs between ages 60 and 70, though the disease occurs across all age groups.
• Trend: Incidence is increasing worldwide, driven by aging populations and the explosion in NSAID and PPI use.
• Misdiagnosis: Studies suggest the average time from symptom onset to correct diagnosis exceeds 2–3 years, during which patients are commonly labeled with IBS.

The key clinical differentiator from IBS: nocturnal diarrhea. Irritable bowel syndrome almost never wakes patients from sleep. Microscopic colitis frequently does. When a patient reports chronic watery diarrhea that occurs at night, the diagnosis of IBS should be reconsidered and colonoscopy with biopsies pursued.

Drug Triggers: The Critical Modifiable Factor

The most actionable dimension of microscopic colitis — and the one most frequently overlooked in clinical practice — is its association with commonly prescribed and over-the-counter medications. In a significant proportion of patients, the disease is drug-induced, and removing the offending medication produces dramatic improvement within weeks without any pharmacological therapy.

Pathophysiology: Why the Colon Floods

Understanding how microscopic colitis produces its characteristic secretory diarrhea requires tracing the injury from luminal trigger to clinical symptom.

The colon's normal function includes absorbing water from intestinal contents — up to 1.5 liters per day pass through the colon, and most is reclaimed. This absorption depends on an intact epithelial barrier and normal ion transport mechanisms. In microscopic colitis, multiple mechanisms disrupt this process:

1. Luminal triggers arrive: Drugs (NSAIDs, PPIs), bile acids, and possibly pathogenic bacteria reach the colonic mucosa. In susceptible individuals — likely with genetic immune dysregulation — these triggers initiate an abnormal mucosal immune response.
2. Immune activation: T-lymphocytes are recruited to the epithelium (the intraepithelial lymphocytes that define LC) and the lamina propria. Cytokine release — particularly interferon-gamma and TNF-alpha — increases epithelial permeability and directly impairs ion transport.
3. Collagen deposition (CC): In collagenous colitis, activated myofibroblasts beneath the epithelium deposit excess collagen, creating the thickened band that physically impedes water and ion exchange across the epithelial surface.
4. Secretory diarrhea: The result is a net shift from absorption to secretion. Unlike osmotic diarrhea (which stops with fasting), secretory diarrhea persists even when the patient eats nothing — a distinguishing clinical feature. The stool osmotic gap is typically less than 50 mOsm/kg.

Bile acids play a secondary but important role. Excess bile acids reaching the colon — whether from ileal malabsorption or altered hepatic synthesis — act as direct colonic secretagogues and may perpetuate inflammation. This is why cholestyramine (a bile acid sequestrant) can help as an adjunct therapy even when the primary trigger has been removed.

Diagnosis: Why the Biopsy Matters More Than the Colonoscopy

Microscopic colitis is diagnosed exclusively by histopathology. A normal-appearing colonoscopy, while necessary to exclude macroscopic disease (ulcerative colitis, Crohn's, colorectal cancer), provides no diagnostic information about microscopic colitis. The critical steps:

Colonoscopy with Segmental Biopsies

Because microscopic colitis has a patchy distribution, biopsies must be taken from multiple anatomical sites — the right colon, transverse colon, left colon, and rectum. A single biopsy from the rectosigmoid — the most common sampling strategy for other conditions — will miss microscopic colitis in a significant proportion of cases. Some patients have disease confined to the right colon.

The pathology report should specify: intraepithelial lymphocyte count per 100 colonocytes, collagen band thickness in micrometers, and the presence or absence of surface epithelial damage. These details determine the subtype and inform treatment decisions.

Rule Out Celiac Disease

Anti-tTG IgA should be measured in every patient newly diagnosed with microscopic colitis. The 15–20% coexistence rate with celiac disease is not a coincidence — both conditions share autoimmune underpinnings and respond to immunologic triggers. In patients with both conditions, strict gluten elimination may dramatically improve microscopic colitis symptoms without any pharmacological intervention, because gluten-driven intestinal inflammation amplifies the colonic immune response.

Stool Studies

Fecal calprotectin is elevated in approximately 50–70% of active microscopic colitis — useful as a non-invasive marker of inflammation and for monitoring treatment response, though not diagnostic. Stool culture and Clostridioides difficile PCR should be obtained to exclude infectious causes, particularly in patients with recent antibiotic exposure.

Treatment: A Stepwise Approach

Treatment of microscopic colitis follows a clear stepwise logic, and the most effective intervention for a significant proportion of patients costs nothing and requires no prescription: remove the drug causing it.

Step 1: Drug Discontinuation

Every patient with a new diagnosis of microscopic colitis should have their medication list reviewed systematically for NSAIDs, PPIs, SSRIs, statins, and beta-blockers. In patients on long-term NSAIDs for pain or PPIs for GERD, discontinuation — where clinically feasible — should precede any pharmacological therapy. Allow 4–8 weeks for response before concluding the drug was not the cause.

Clinical response to PPI discontinuation can be striking and rapid — some patients experience complete resolution within two to four weeks. This represents one of the most direct cause-and-effect relationships in clinical gastroenterology, and yet it is routinely missed because the PPI was prescribed years before symptoms began.

Step 2: Test and Treat for Celiac Disease

If anti-tTG IgA is positive, the patient should be referred for duodenal biopsy to confirm celiac disease and initiated on a strict gluten-free diet. The gluten-free diet alone may resolve microscopic colitis symptoms in patients with both conditions, avoiding immunosuppressive therapy entirely.

Step 3: Budesonide — The Gold Standard

For patients who do not respond to drug discontinuation and celiac management, enteric-coated budesonide is the ECCO (European Crohn's and Colitis Organisation) guideline-recommended first-line pharmacotherapy. Budesonide is a synthetic corticosteroid with high topical anti-inflammatory activity and extensive first-pass hepatic metabolism — meaning it acts locally in the colon with minimal systemic glucocorticoid side effects.

The BUDESONIDE trial demonstrated an 8-week remission rate of 80% in collagenous colitis vs. 17% for placebo — an NNT of approximately 2. This makes budesonide one of the most efficacious treatments in all of inflammatory bowel disease. The standard induction dose is 9mg once daily for 8 weeks, tapering to 6mg for collagenous colitis maintenance.

The critical limitation: relapse rates are high. 50–80% of patients relapse after budesonide is stopped. For patients who relapse repeatedly, low-dose maintenance budesonide (3–6mg/day) is used long-term, accepting the cumulative risk of systemic steroid effects (adrenal suppression, bone density loss).

Adjunct Options

• Cholestyramine (4g with meals, 1–3 times daily): Bile acid sequestrant. Binds bile acids in the colon, reducing their secretagogue effect. Useful adjunct, particularly in patients with concurrent bile acid malabsorption.
• Bismuth subsalicylate (2 tablets TID × 8 weeks): Small RCTs positive. Anti-inflammatory, antimicrobial, mucosal protective. A reasonable option for mild-moderate disease or as adjunct.
• Mesalamine: Modest evidence. Some benefit reported in observational studies. Generally less effective than budesonide but sometimes used for maintenance.
• Probiotics: Limited evidence in microscopic colitis specifically. General gut health benefits may support the microbiome during active treatment.

Refractory Disease

A minority of patients fail budesonide and adjunct therapy. For refractory microscopic colitis, anti-TNF biologics — particularly infliximab — have shown efficacy in small case series and represent the current off-label rescue option. This population should be managed at a specialist IBD center.

Diet Management: What the Evidence Actually Supports

Dietary modification in microscopic colitis is not curative but plays a meaningful supportive role during active flares. The evidence base is thinner than for pharmacological therapy, but several dietary principles are consistently supported by pathophysiology and clinical experience.

Coffee and Caffeine: Reduce During Flares

Caffeine increases intestinal permeability by modulating tight junction proteins and stimulates colonic motility via adenosine receptor antagonism. For patients in active flare, reducing or eliminating coffee is a low-risk, high-potential intervention. Some patients report significant symptom relief within days of coffee elimination. Green tea, with its lower caffeine load and L-theanine content, is a reasonable substitute.

Gluten: Mandatory Elimination If Celiac Coexists

In patients with confirmed celiac disease and microscopic colitis, a strict gluten-free diet is not optional — it is a cornerstone of treatment. Even in patients without celiac disease, some practitioners trial gluten elimination empirically, though evidence for this in seronegative patients is anecdotal.

Fat: Reduce During Active Disease

Dietary fat stimulates cholecystokinin release, which drives bile acid secretion from the gallbladder. High-fat meals increase the colonic bile acid load, exacerbating secretory diarrhea in susceptible patients. During flares, a low-fat diet (less than 40–50g fat per day) is recommended to reduce this stimulus. This is particularly relevant in patients using cholestyramine as an adjunct.

Insoluble Fiber: Reduce During Active Flares

Insoluble fiber (found in whole grain cereals, raw vegetables, wheat bran) increases stool bulk and accelerates colonic transit — the opposite of what a patient with 10 loose stools per day needs. During flares, switching to low-insoluble-fiber, easily digestible foods is practical and symptom-supportive. Soluble fiber (oats, bananas, cooked vegetables) is generally better tolerated and helps form stool.

Associated Autoimmune Conditions

Microscopic colitis does not exist in isolation. Its autoimmune underpinnings connect it to a broader family of immune-mediated conditions:

• Celiac disease: 15–20% coexistence — mandatory testing at diagnosis
• Rheumatoid arthritis: Elevated prevalence in MC patients; shares the burden of NSAID use (which then worsens MC)
• Sjögren's syndrome: Associated — especially in older women, the primary demographic for MC
• Thyroid disease (both hypothyroid and autoimmune thyroiditis): Elevated prevalence in MC cohorts
• Type 1 diabetes and other organ-specific autoimmunity

The clinical implication: when a patient presents with microscopic colitis, a broader autoimmune screen is justified. Addressing comorbid autoimmune conditions — and critically, optimizing the medications used to treat them — may have direct impact on microscopic colitis activity.

Prognosis and Long-Term Course

The natural history of microscopic colitis is more variable than often described. While the classic narrative is chronic, relapsing-remitting diarrhea requiring long-term management, a meaningful subset of patients — particularly those whose disease was drug-induced — experience complete remission after trigger removal and do not relapse.

Key prognostic factors:

• Patients who successfully discontinue the offending drug (especially NSAIDs or PPIs) have the best long-term outcomes.
• Those who require budesonide face high relapse rates (50–80%) and may need indefinite maintenance therapy.
• Microscopic colitis does not increase colorectal cancer risk — an important reassurance for patients who associate any colonic inflammation with cancer risk.
• Quality of life impact is substantial during active disease — equivalent to other IBDs — but many patients achieve durable remission with appropriate management.